Status | Study |
Recruiting |
Study Name: South Australian Meningococcal B Vaccine Herd Immunity Study Condition: Meningococcal Disease Date: 2017-03-17 Interventions: Biological: Licensed 4CMenB vaccine Two doses (0.5 mL each) of Bexsero ® vaccine at least 1 month t |
Recruiting |
Study Name: PRIME Follow up - Quadri Meningo Vacinees Condition: Meningococcal Disease Date: 2016-06-15 Interventions: Other: venepuncture only single venepuncture |
Active, not recruiting |
Study Name: Safety and Immunogenicity of an Aluminium Hydroxide/LHD153R Adjuvanted Meningococcal C-CRM197 Conjugate Vaccine Condition: Meningococcal Disease Date: 2015-12-21 Interventions: Biological: MenC-CRM conjugate vaccine with 12.5 ug LHD153R |
Active, not recruiting |
Study Name: Evaluation of Antibody Persistence Following 4 MenACWY Vaccinations Condition: Meningococcal Disease Date: 2015-05-13 Interventions: Biological: Menveo® Four Intramuscular doses of MenACWY vaccine at 2, 4, 6 and 12 months of age fol |
Completed |
Study Name: A Study to Evaluate 4-year Antibody Persistence and Booster Response Following MenABCWY Vaccination in Healthy Adolescents and Young Adults Who Previously Participated in Studies V102_02 (NCT01210885) and V102_02E1 (NCT01367158) Condition: Meningococcal Disease Date: 2015-05-04 Interventions: Biological: MenABCWY+OMV vaccine Intramuscular injection of a single dose at Day 1 to subjects in the Me |
Completed |
Study Name: Assessing the Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents Condition: Meningococcal Disease Date: 2014-11-05 Interventions: Biological: Meningococcal ABCWY |
Active, not recruiting |
Study Name: Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Infant Study Condition: Meningococcal Disease Date: 2014-10-27 Interventions: Biological: Meningococcal quadrivalent CRM-197 conjugate vaccine This study is strictly observational. D |
Completed |
Study Name: Safety and Immunogenicity of Novartis Meningococcal B Vaccine When Administered to Immunocompromised Children and Adolescents Compared to Healthy Subjects. Condition: Meningococcal Disease Date: 2014-05-15 Interventions: Biological: rMenB+OMV 2 doses of vaccine 2 months apart |
Completed |
Study Name: Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents Condition: Meningococcal Disease Date: 2014-05-06 Interventions: Biological: MenABCWY Effective |
Completed |
Study Name: Safety and Immunogenicity of One Dose of Novartis' Meningococcal ACWY-CRM Vaccine and GlaxoSmithKline Biologicals' Meningococcal ACWY-TT Vaccine in Healthy Toddlers Condition: Meningococcal Disease Date: 2013-11-11 Interventions: Biological: MenACWY-CRM MenACW |